,
2 min read
China’s pharmaceutical market is one of the fastest-growing globally, and 2026 is shaping up to be a pivotal year for Regulatory compliance and market entry. With evolving policies from the National Medical Products Administration (NMPA), global pharma companies need to be fully prepared to meet China’s requirements for drug registration, medicinal products, and Regulatory affairs.
This checklist provides a practical guide for companies planning market entry, lifecycle management, or Regulatory compliance in China in 2026.
1. Understand the Regulatory Authority & Framework
- Confirm that NMPA is the Regulatory body for medicinal products.
- Review Drug Administration Law, its implementing regulations, and Provisions for Drug Registration.
- Stay updated with any NMPA guidance documents, policy announcements, and technical specifications.
2. Marketing Authorization Holder (MAH) Requirements
- Appoint a Local Responsible Person for overseas MAHs as required by NMPA.
- Ensure all contact information, responsibilities, and documentation for the local representative are current.
3. Dossier Preparation
- Compile a complete CTD/eCTD dossier including administrative, quality (CMC), clinical, and safety data.
- Include API/DMF information and certificates of suitability.
- Validate that the electronic submission format aligns with NMPA guidance to avoid rejection.
4. Drug Classification & Registration Pathways
- Verify product category: chemical drugs, biologicals, biosimilars, TCM, or generics.
- Identify the appropriate Regulatory pathway, as classification determines submission requirements and timelines.
5. Pre-Approval Import and Local Filing
- Prepare import filings for pre-approval batches if required.
- Ensure all imported products meet Chinese GMP and quality standards.
6. Good Manufacturing Practice (GMP) Compliance
- Ensure full compliance with NMPA GMP regulations, including new annexes for excipients and packaging.
- Conduct internal audits to verify readiness for NMPA inspections.
7. Re-Registration & Renewal
- Plan for re-registration 12–6 months before expiry of existing approvals.
- Prepare updated data and documents as per new requirements for re-registration.
8. Pharmacovigilance & Post-Marketing Surveillance
- Maintain an effective pharmacovigilance system in China.
- Monitor adverse events, submit safety reports, and maintain documentation in compliance with NMPA expectations.
9. Regulatory Tracking & Updates
- Monitor NMPA announcements and circulars for updates on review timelines, technical requirements, and policy changes.
- Participate in industry forums and workshops to stay ahead of Regulatory trends.
10. Communication & Local Representation
- Maintain active communication with NMPA officials and local Regulatory contacts.
- Track all submissions, responses, and follow-ups to ensure timely approvals.
Practical Actions for 2026
- Update Local Responsible Person information and documentation.
- Align dossiers with the latest CTD/eCTD formats and NMPA guidance.
- Prepare for GMP compliance audits for Marketing Authorization Applications, including related APIs, excipients and packaging materials.
- Schedule re-registration submissions ahead of certificate expiry.
- Ensure import documentation and approvals are in place for pre-approval batches.
Conclusion
The Regulatory landscape in China is rapidly evolving, emphasizing quality, safety, and international harmonization. Proactive preparation using this 2026 readiness checklist will help pharma companies achieve faster approvals, compliant market entry, and efficient lifecycle management in China.
For comprehensive support with drug registration, GMP compliance, and Regulatory strategy in China, connect with our Regulatory Affairs experts today.
